on ABIONYX (EPA:ABNX)
ABIONYX Pharma: Review of the first quarter of 2026
ABIONYX Pharma announced revenue of €0.8 million for the first quarter of 2026, down from 2025. The biopharmaceutical company leverages its proprietary apoA-I-based technology platform to develop innovative therapies. No revenue is generated from its core business, as its products are offered under a compassionate access program. Cash and cash equivalents remained stable at €2.8 million as of March 31, 2026.
The company has secured financing through a capital increase and a non-dilutive loan, guaranteeing its financial stability until the end of 2028. This financing will support the development of CER-001 for orphan deficiencies and a Phase 2b clinical trial in sepsis.
R. P.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all ABIONYX news